Storm Therapeutics News and Activities

Acquisition, funding and merger involving Storm Therapeutics.

• Storm Therapeutics has just announced a $56 Million fundraising (posted on April 16 2026).

View the org chart displaying its 13 main executives

Most searched biographies at Storm Therapeutics

• Jerry McMahon, Chief Executive Officer & President
• Paul Workman, Director
• Tony Kouzarides, Director

Popular executive movements at Storm Therapeutics

• Atif Abbas, Chief Medical Officer, has left the company  (posted on April 8 2026).

Create your alert
to follow the executive moves at Storm Therapeutics.

Storm Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Storm Therapeutics

• STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM The
• STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• Events | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• View more press releases Close

Social media about Storm Therapeutics

• Storm Therapeutics on Wikipedia, Google News & Yahoo Finance
• Storm Therapeutics on LinkedIn, X (Twitter) & YouTube